Semaglutide, Tirzepatide and Retatrutide: Single, Dual and Triple Receptor Agonism

Semaglutide, Tirzepatide and Retatrutide are often grouped together, but their receptor targets and evidence histories are different. Semaglutide activates the GLP-1 receptor. Tirzepatide activates GIP and GLP-1 receptors. Retatrutide is being investigated as an agonist at GIP, GLP-1 and glucagon receptors.

The words single, dual and triple describe receptor targeting. They are not a scale that automatically ranks effectiveness or safety. They also should not be replaced by the product nicknames “GLP-1,” “GLP-2” and “GLP-3.” Using the actual molecule names keeps the discussion connected to the correct studies and avoids confusing receptor biology with a numbered product series.

What changes at the receptor level?

Semaglutide is the active substance in authorized medicines including Wegovy. The European Medicines Agency describes its GLP-1 receptor activity in relation to appetite regulation and reduced food intake. This supplies a clear mechanistic starting point, but the authorization concerns the evaluated medicinal product and its defined uses. EMA: Wegovy.

Tirzepatide, the active substance in Mounjaro, engages both GIP and GLP-1 receptors. It is one molecule with activity at two receptor systems, rather than a mixture of Semaglutide and a separate GIP product. The receptor profile helps explain why it is studied as a distinct intervention; clinical comparisons still require clinical data. EMA: Mounjaro.

Retatrutide adds glucagon-receptor activity to GIP and GLP-1 agonism. Its development asks whether this combined pharmacology can produce clinically useful metabolic effects with an acceptable safety profile. The phase 2 obesity trial established an important clinical signal, while also recording gastrointestinal adverse events and changes in heart rate. More receptor targets do not remove the need to measure harms. Retatrutide phase 2 primary report.

The table describes pharmacology and evidence status. It is not a prescribing guide or a comparison of research-vial quality.

Why percentages need their study context

In STEP 1, Semaglutide was compared with placebo in adults with overweight or obesity who did not have diabetes. At 68 weeks, the reported mean weight change was −14.9% with Semaglutide and −2.4% with placebo; both groups received a lifestyle intervention. These figures belong to that population and trial design. They are not a universal prediction for every person or every Semaglutide formulation. STEP 1 primary report.

A different result from another trial can reflect differences in participants, duration, comparator, treatment exposure or statistical analysis. Comparing the largest percentage printed for each molecule ignores those differences. It is particularly misleading when one figure includes an initial lifestyle phase and another does not, or when one analysis assumes continued treatment and another includes discontinuation.

The direct Tirzepatide–Semaglutide comparison

SURMOUNT-5 provides stronger evidence for a particular comparison because participants were randomized between the two interventions within the same trial. It enrolled 751 adults with obesity without type 2 diabetes and used an open-label design. At 72 weeks, estimated mean weight changes were −20.2% with Tirzepatide and −13.7% with Semaglutide. Gastrointestinal events were the most commonly reported adverse events in both groups.

That supports the trial’s conclusion about weight and waist reduction under its tested conditions. It does not establish superiority for every health outcome, population, formulation or future regimen. The comparison is informative precisely because its boundaries are identifiable. SURMOUNT-5 primary report.

Where Retatrutide stands at this review date

Retatrutide’s clinical program has advanced beyond the original phase 2 publication. In July 2026, Lilly reported positive topline results from TRIUMPH-2 and TRIUMPH-3. The latter enrolled people with severe obesity and established cardiovascular disease, with or without type 2 diabetes. The same announcement described Retatrutide as investigational and outlined a planned FDA submission in the first quarter of 2027.

These are sponsor-reported results and a planned regulatory step, not an approval announcement. A complete assessment must distinguish topline releases from full peer-reviewed reports and examine adverse events, missing data and the analysis used for each endpoint. Lilly update, July 23, 2026.

Reading the evidence as a researcher

Start with the actual molecule, then identify the population and the question the study was designed to answer. Check the comparator, follow-up period and primary endpoint before interpreting a number. Read safety and discontinuation findings alongside efficacy. Finally, separate the investigated medicine from products that share a compound name but have not undergone the same clinical and regulatory evaluation.

For a broader reading path, use this comparison alongside the molecule-specific articles on Semaglutide, Tirzepatide and Retatrutide. Each has a distinct history; the comparison explains how to read those histories together.

Evidence limitations

The six sources cited here do not establish a single head-to-head ranking of all three molecules. Findings from separate trials should not be presented as if they came from one randomized comparison. Regulatory status applies to specific products, jurisdictions and indications, and may change after the review date. Research-grade vials are not interchangeable with authorized medicines or the materials used in clinical trials.

Reviewed September 12, 2026. This article is educational and does not provide instructions for human use.

Primary references

• EMA — Wegovy assessment and product information.
• EMA — Mounjaro assessment and product information.
• Jastreboff et al. — Retatrutide phase 2 trial, 2023.
• Wilding et al. — STEP 1, 2021.
• Aronne et al. — SURMOUNT-5, 2025.
• Lilly — TRIUMPH-2/3 topline update, July 2026.